Search company, investor...

Predict your next investment

EQT Life Sciences company logo
Venture Capital
FINANCE | Investment Firms & Funds
eqtgroup.com/private-capital/life-sciences

Investments

214

Portfolio Exits

51

Funds

13

Partners & Customers

2

Service Providers

1

About EQT Life Sciences

EQT Life Sciences is a venture capital firm specializing in early- to mid-stage life sciences companies. It provides pre-seed and pre-series A- funding to healthcare, biotechnology, and other life sciences companies. It was formerly known as Life Sciences Partners. It was founded in 1987 and is based in Amsterdam, Netherlands.

Headquarters Location

Johannes Vermeerplein 9

Amsterdam, 1071 DV,

Netherlands

31 20 664 5500

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest EQT Life Sciences News

AlzeCure CEO Martin Jönsson to Present at the International Investor Conference BioCapitalEurope

Jan 31, 2024

AlzeCure CEO Martin Jönsson to Present at the International Investor Conference BioCapitalEurope STOCKHOLM, SWEDEN / ACCESSWIRE / January 31, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that its CEO Martin Jönsson will present the company at the investor conference BioCapitalEurope 2024, which is organized by EQT Life Sciences. Martin Jönsson will present AlzeCure and its portfolio of preclinical and clinical drug candidates for CNS diseases, with a focus on Alzheimer's disease and pain. The presentation will be held on February 8, 2024, at 4.40pm at Hotel Sofitel Legend The Grand Amsterdam, Amsterdam, the Netherlands. BioCapitalEurope is Europe's premier life sciences investment conference, organized by EQT Life Sciences, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe. For more information, please contact Martin Jönsson, CEO About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se . Image Attachments Editor Details PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us Version: 2022.9.21.3 You are leaving PharmiWeb.com Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com. PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Continue

EQT Life Sciences Investments

214 Investments

EQT Life Sciences has made 214 investments. Their latest investment was in Onera as part of their Series C on January 16, 2024.

CBI Logo

EQT Life Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/16/2024

Series C

Onera

$32.73M

Yes

3

1/5/2024

Series B

Vico Therapeutics

$59.01M

No

3

12/18/2023

Series A - III

Luma Vision

$22M

No

4

12/12/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/14/2023

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/16/2024

1/5/2024

12/18/2023

12/12/2023

11/14/2023

Round

Series C

Series B

Series A - III

Series A

Series C

Company

Onera

Vico Therapeutics

Luma Vision

Subscribe to see more

Subscribe to see more

Amount

$32.73M

$59.01M

$22M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

4

10

10

EQT Life Sciences Portfolio Exits

51 Portfolio Exits

EQT Life Sciences has 51 portfolio exits. Their latest portfolio exit was Atlantic Therapeutics on September 06, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/6/2023

Acquired

$99M

6

11/22/2022

Reverse Merger

$99M

4

10/21/2021

IPO

$99M

Public

3

2/24/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/6/2023

11/22/2022

10/21/2021

2/24/2021

2/5/2021

Exit

Acquired

Reverse Merger

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

6

4

3

10

10

EQT Life Sciences Fund History

13 Fund Histories

EQT Life Sciences has 13 funds, including LSP Dementia Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/29/2023

LSP Dementia Fund

$281.89M

2

2/11/2022

LSP 7

$1,140M

2

3/10/2020

LSP 6

Multi-Stage Venture Capital

Closed

$600M

2

12/12/2017

LSP Health Economics Fund II

Subscribe to see more

Subscribe to see more

$99M

10

6/2/2016

Life Sciences Partners V

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/29/2023

2/11/2022

3/10/2020

12/12/2017

6/2/2016

Fund

LSP Dementia Fund

LSP 7

LSP 6

LSP Health Economics Fund II

Life Sciences Partners V

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$281.89M

$1,140M

$600M

$99M

$99M

Sources

2

2

2

10

10

EQT Life Sciences Partners & Customers

2 Partners and customers

EQT Life Sciences has 2 strategic partners and customers. EQT Life Sciences recently partnered with EQT Partners on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/10/2021

Partner

Sweden

LSP and EQT join forces in healthcare investing

The life science industry is going through a phase of unprecedented innovation and , through the partnership with LSP , EQT AB will be able to participate in this growth opportunity and open up doors for attractive new investments in the space . ''

1

11/24/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

11/10/2021

11/24/2015

Type

Partner

Partner

Business Partner

Country

Sweden

United States

News Snippet

LSP and EQT join forces in healthcare investing

The life science industry is going through a phase of unprecedented innovation and , through the partnership with LSP , EQT AB will be able to participate in this growth opportunity and open up doors for attractive new investments in the space . ''

Subscribe to see more

Subscribe to see more

Sources

1

10

EQT Life Sciences Service Providers

1 Service Provider

EQT Life Sciences has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Series A

Counsel

General Counsel

Service Provider

Associated Rounds

Series A

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

EQT Life Sciences Team

17 Team Members

EQT Life Sciences has 17 team members, including current Founder, Owner, Martijn Keijwegt.

Name

Work History

Title

Status

Martijn Keijwegt

Founder, Owner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Martijn Keijwegt

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Owner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.